With shrinking national budgets, increasing deficits, demands for welfare assistance, and economies which are struggling to recover from month long lock-downs and harsh restrictive measures, investing in the unknown is a difficult decision to make.
The best chance of success for any country is to participate in an endeavour which diversifies and broadens access to a broad portfolio of possible vaccine candidates.
Developing the capacity to rapidly fill vaccine vials and finish packaging vaccines for manufacturers in a public health emergency, is an issue of national security.
The National Surveillance on Antibiotic Resistance has indicated that we have almost every variety of antibiotic resistance thus far documented including some which have not yet made an appearance in other parts of the world.